Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • Find a professional representative
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • EPC Guidelines
      • PCT-EPO Guidelines
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • A glimpse of the planned activities
      • Kids’ collaborative art competition
      • 50 Leading Tech Voices
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Select Committee documents
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
            • Go back
            • Overview
            • BG - Federated Register Service
            • GB - Federated Register Service
            • NL - Federated Register Service
            • MK - Federated Register Service
            • ES - Federated Register Service
            • GR - Federated Register Service
            • SK - Federated Register Service
            • FR - Federated Register Service
            • MT - Federated Register Service
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • Find a professional representative
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • EPC Guidelines
        • Go back
        • Overview
        • Archive
      • PCT-EPO Guidelines
        • Go back
        • Overview
        • Archive
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
        • IP clinics
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Overview
      • 50 Leading Tech Voices
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
      • Surveys
        • Go back
        • Overview
        • Search services
        • Examination services, final actions and publication
        • Opposition services
        • Patent filings
          • Go back
          • Overview
          • Detailed methodology
          • Archive
        • Online Services
        • Patent information
          • Go back
          • Overview
          • Innovation process survey
        • Customer services
        • Filing services
        • Website
        • Survey on electronic invoicing
        • Companies innovating in clean and sustainable technologies
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
Board of Appeals
Decisions

Recent decisions

Overview
  • 2023 decisions
  • 2022 decisions
  • 2021 decisions
https://www.epo.org/en/node/t071170eu1
  1. Home
  2. T 1170/07 (Tethrahydrolipstatin for treating NIDDM/F. HOFFMANN-LA ROCHE AG) 13-03-2012
Facebook Twitter Linkedin Email

T 1170/07 (Tethrahydrolipstatin for treating NIDDM/F. HOFFMANN-LA ROCHE AG) 13-03-2012

European Case Law Identifier
ECLI:EP:BA:2012:T117007.20120313
Date of decision
13 March 2012
Case number
T 1170/07
Petition for review of
-
Application number
98908008.0
IPC class
A61K 31/365
A61P 3/10
Language of proceedings
EN
Distribution
DISTRIBUTED TO BOARD CHAIRMEN (C)

Download and more information:

Decision in EN 39.2 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Use of tethrahydrolipstatin in the treatment of diabetes type II

Applicant name
F. Hoffmann-La Roche AG
Opponent name
Ratiopharm GmbH
Board
3.3.02
Headnote
-
Relevant legal provisions
European Patent Convention Art 123(2)
European Patent Convention Art 113(1)
European Patent Convention R 103
Keywords
-
Catchword
-
Cited decisions
G 0002/10
T 0468/99
T 0246/08
Citing decisions
T 0135/10
T 1668/13
T 2027/13
T 0108/14
T 0044/20
T 2015/18

I. European patent No. 1 017 408 based on application No. 98 908 008.0 was granted on the basis of 11 claims. The sole independent claim reads as follows:

"1. The use of tetrahydrolipstatin for the manufacture of an oral pharmaceutical preparation for treating type II diabetes mellitus per se, the amount of tetrahydrolipstatin to be employed in unit dosage form, which consists essentially of tetrahydrolipstatin formulated as an oral composition, the amount of tetrahydrolipstatin being effective to alleviate or cure type II diabetes mellitus per se and in the range of from 60 to 720 mg of tetrahydrolipstatin per day."

II. An opposition was filed against the patent. The patent was opposed under Article 100(a) EPC for lack of novelty and inventive step and for non-patentability under Article 52(4) EPC, under Article 100(b) EPC for insufficiency of disclosure and under Article 100(c) EPC for amendments that contained subject-matter extending beyond the content of the parent application as filed.

III. The documents cited during the opposition and appeal proceedings included the following:

(4) EP-A-0 638 317

(11) A.J. Scheen, et al., Diabete Metab. (1993), 19, 547-559

(13) R.R. Wing, et al., Arch. Intern. Med. (1987), vol. 147, 1749-1753

IV. The appeal lies from an interlocutory decision of the opposition division pronounced on 3 May 2007 and posted on 14 May 2007 maintaining the patent on the basis of the claims as granted and a description amended in the course of the opposition proceedings.

V. In said decision the opposition division decided that the ground for opposition under Article 100(c) EPC did not prejudice the maintenance of the patent in the form of the claims as granted, as the original application made it clear that the intended treatment concerned NIDDM (non-insulin dependent diabetes mellitus = type II diabetes mellitus) itself rather than potential risk factors thereof, so that the feature "type II diabetes mellitus per se" had a basis in the original application. Nor did the introduction of the unit dosage and the replacement of "comprising" by "consisting essentially of", which was introduced in order to exclude the presence of further active agents, prejudice the maintenance of the contested patent under Article 100(c) EPC.

Furthermore, the opposition division concluded that the priority was validly claimed and that the claimed subject-matter was not excluded from patentability by Article 52(4) EPC 1973. The claimed subject-matter was considered novel, as document (4) concerned improvement or elimination of the risk factors of NIDDM rather than its treatment per se.

Regarding inventive step, the opposition division defined the finding of alternative ways of improving NIDDM as the problem to be solved vis-à-vis document (13), the solution of which in the form of the use according to claim 1 as granted was not rendered obvious by any of the available prior-art documents. Making reference to Article 69 EPC, the opposition division concluded that the amendment of the description as sole amendment was allowable under Rule 57(a) EPC 1973.

The decision under appeal does not, however, contain any reasoning as to why the invention according to the claims as granted is sufficiently disclosed.

VI. The opponent (appellant) lodged an appeal against that decision.

VII. In the annex to the summons to oral proceedings pursuant to Article 15(1) RPBA, the board gave its preliminary opinion in connection with the ground for opposition under Article 100(c) EPC and the reimbursement of the appeal fee according to Rule 103(1)(a) EPC. According to this preliminary opinion, neither of the features "type II diabetes mellitus per se" and "60 to 720 mg of tetrahydrolipstatin per day" had a basis in the original application.

VIII. In a letter dated 9 February 2012, the respondent submitted arguments against the objections raised by the board in the annex to the summons to oral proceedings and filed auxiliary requests I to III.

IX. With a further letter dated 8 March 2012, the respondent submitted a main request and an auxiliary request I (corresponding to auxiliary requests II and III filed with letter dated 9 February 2012).

X. The appellant informed the board with a letter dated 29 February 2012 that it would not be attending the oral proceedings scheduled for 13 March 2012.

XI. Oral proceedings were held before the board on 13 March 2012. In the course of the oral proceedings, the respondent filed auxiliary requests II and III.

XII. The independent claims of the requests on file read as follows:

(i) Main request:

"1. The use of tetrahydrolipstatin for the manufacture of an oral pharmaceutical preparation for treating type II diabetes mellitus per se, the amount of tetrahydrolipstatin to be employed in unit dosage form, which consists essentially of tetrahydrolipstatin formulated as an oral composition, the amount of tetrahydrolipstatin being effective to alleviate or cure type II diabetes mellitus per se and in the range of from 60 to 720 mg of tetrahydrolipstatin per day, wherein the pharmaceutical preparation is to be administered from two to three times per day."

(ii) Auxiliary request 1:

"1. The use of tetrahydrolipstatin for the manufacture of an oral pharmaceutical preparation for treating type II diabetes mellitus, the amount of tetrahydrolipstatin to be employed in unit dosage form, which consists essentially of tetrahydrolipstatin formulated as an oral composition, the amount of tetrahydrolipstatin being effective to alleviate or cure type II diabetes mellitus and in the range of from 60 to 720 mg of tetrahydrolip-statin per day, wherein the pharmaceutical preparation is to be administered from two to three times per day."

(iii) Auxiliary request 2:

"1. The use of tetrahydrolipstatin for the manufacture of an oral hypoglycemic pharmaceutical preparation for treating type II diabetes mellitus, the amount of tetrahydrolipstatin to be employed in unit dosage form, which consists essentially of tetrahydrolipstatin formulated as an oral composition, the amount of tetrahydrolipstatin being effective to alleviate or cure type II diabetes mellitus and in the range of from 60 to 720 mg of tetrahydrolipstatin per day, wherein the pharmaceutical preparation is to be administered from two to three times per day."

(iv) Auxiliary request 3:

"1. The use of tetrahydrolipstatin for the manufacture of an oral pharmaceutical preparation for treating type II diabetes mellitus in a non-obese subject, the amount of tetrahydrolipstatin to be employed in unit dosage form, which consists essentially of tetrahydro-lipstatin formulated as an oral composition, the amount of tetrahydrolipstatin being effective to alleviate or cure type II diabetes mellitus in a non-obese subject and in the range of from 60 to 720 mg of tetrahydrolip-statin per day, wherein the pharmaceutical preparation is to be administered from two to three times per day."

XIII. The appellant's arguments regarding the objections raised in connection with the allowability of the amendments and the requirements of Article 123(3) EPC can be summarised as follows:

The introduction of the feature "for treating type II diabetes mellitus per se", which had not been originally disclosed, changed the technical teaching of the contested patent. Now, the claimed use involved direct treatment of type II diabetes mellitus (NIDDM), i.e. treatment independent of weight loss, for which there was no basis in the original application. On the contrary: example 4 unambiguously showed that the glycemic control was not independent of weight loss. Moreover, there was no basis in the original application for the substitution of "consisting essentially of" for "comprising" either. According to the established jurisprudence of the boards of appeal, the term "consisting essentially of" excluded the presence of further compounds in addition to the active agent that might influence the properties of the oral pharmaceutical preparation defined in the claim. In view of the fact that excipients had a considerable influence on the performance of the preparation, neither examples 1 to 3 nor any other disclosure of the original application could serve as a basis for "consisting essentially of". Deletion of the term "per se" from claim 1 of auxiliary request I resulted in an extension of the scope of protection, which was not allowable under Article 123(3) EPC.

XIV. The respondent's arguments in connection with the allowability of the amendments and the requirements of Article 123(3) EPC can be summarised as follows:

Regarding the main request, the respondent emphasised that claim 1 concerned a second medical use claim. Second medical use claims were intention-based and linked to the treatment of a specific disease. The introduction of "per se" did not change the meaning of the claim at all but merely emphasised this aspect. In contrast to the prior art, which was directed to the use of tetrahydrolipstatin for treating obesity and hyperlipidemia, the present invention concerned, for the first time, direct treatment of NIDDM by means of glycemic control, which meant treatment independent of weight loss. This teaching was clearly expressed on pages 1 and 2 of the description, so that the specific examples were not needed as a basis for the amendments. Example 4, which did not relate to a formulation but concerned a clinical study involving patients stabilised with sulfonylureas, was irrelevant for interpreting the subject-matter defined in the claims.

In connection with the substitution of "consisting essentially of" for "comprising", reference was made to decision T 0468/99 of 16 May 2003, according to which "consisting essentially of" excluded the presence of further pharmaceutically active ingredients beside tetrahydroplistatin. This did not, however, exclude the presence of further compounds such as excipients. The original application as well as examples 1-3 provided a sufficient basis for the teaching that tetrahydro-lipstatin alone was able to achieve the desired pharmacological effect.

As the addition of "per se" did not change the technical teaching of the claimed use, its deletion could not extend the scope of protection either. As a consequence, the subject-matter of auxiliary request I met the requirements of Article 123(3) EPC.

The filing of auxiliary requests II and III was the consequence of the board's reading of the term "per se", which could only be understood at the oral proceedings. As a consequence, it had not been possible to file these requests at an earlier stage of the appeal proceedings. The basis for claim 1 of auxiliary request II was page 1, lines 8-9 ("Other types of treatment include oral hypoglycemics and insulin"), in combination with the disclosure starting on page 1, line 23. The basis for claim 1 of auxiliary request III could be found on page 1, lines 7-8 ("The initial approach in treating obese patients affected with type II diabetes mellitus is weight reduction"), in combination with the disclosure starting on page 1, line 23.

XV. The appellant requested that the decision under appeal be set aside and the European patent No. 1 017 408 be revoked.

XVI. The respondent requested that the appeal be dismissed and the patent be maintained on the basis of the main request or, alternatively, of the first auxiliary request, both submitted with letter of 8 March 2012, or on the basis of the second or third auxiliary request received during oral proceedings of 13 March 2012.

1. The appeal is admissible.

2. Admission of the new requests

2.1 Main request and auxiliary request I

These requests had initially been filed as auxiliary requests II and III with letter dated 9 February 2012 and were resubmitted as main request and auxiliary request I with letter dated 5 March 2012. They constitute a reaction to objections raised in the board's communication pursuant to Article 15(1) RPBA of 17 November 2011. They are therefore admissible (Article 13(1) RPBA).

2.2 Auxiliary requests II and III

These requests were submitted at a late stage of the oral proceedings. In view of the fact that the amendments made were simple, straightforward and foreseeable and that they did not put the opponent and sole appellant into a worse position than if he had not appealed, the board admitted them into the proceedings (Article 13(1) RPBA).

3. Main request - amendments

3.1 Substitution of "consisting essentially of" for "comprising"

Claim 1 of the main request includes a unit dosage form, which consists essentially of tetrahydrolipstatin formulated as an oral composition. Before evaluating whether the original application in its entirety specifically discloses such a unit dosage form, it first has to be established what the term "consisting essentially of", which cannot be found in the original application, means in this context.

The appellant, making reference to decision T 0468/99, argued that "consisting essentially of" meant that the claimed composition must not contain any additional components that might influence the properties of the composition, which even excluded excipients such as PVP or microcrystalline cellulose. The consequence of such an interpretation would be that the unit dosage form formulated as an oral composition would be restricted to tetrahydrolipstatin per se, as any additional compound would have some effect on the properties of the composition.

However, claims should be read in a technically reasonable way. Unit dosage forms formulated as oral compositions necessarily comprise a vehicle or carrier for the active agent, otherwise a safe administration of the active agent is not possible. This requires the presence of further compounds or excipients, which, as was mentioned above, have an influence on the properties of the composition in terms of release rate, stability etc. As a consequence, "consisting essentially of" cannot have this restrictive meaning in the present case. The board concludes that under the specific circumstances of the present case "consisting essentially of" excludes further active agents useful in the treatment of NIDDM but allows the presence of additional compounds forming the carrier of tetrahydrolipstatin.

The passage on page 1, lines 23-27, of the original application discloses that tetrahydrolipstatin, when administered orally, is useful in the treatment and prevention of NIDDM. This disclosure does not specifically mention that tetrahydrolipstatin is used in the absence of further active agents. However, the passage on page 2, lines 22-23, indicates that the pharmaceutical preparations "can also contain still other therapeutically valuable substances" [emphasis by the board], which means that the absence of such therapeutically valuable substances is clearly envisaged. Furthermore, all three formulation examples (examples 1 to 3) concern compositions with tetrahydrolipstatin as the only active agent. The board concludes therefrom that treatment of NIDDM with oral compositions comprising tetrahydrolipstatin as the sole active agent constitutes the most preferred embodiment of the original application. As a consequence, the substitution of "consisting essentially of" for "comprising" is allowable under Article 123(2) EPC.

3.2 Addition of the feature "for treating type II diabetes mellitus per se"

This feature is not explicitly mentioned in the original application either. As a first step, it is necessary to construe the meaning of "for treating type II diabetes mellitus per se". The board agrees with the respondent that this expression defines a treatment which is independent of weight loss. As a next step, it has to be evaluated whether or not the original application contains an implicit disclosure thereof. In this context, it is noted that obesity is a well-known risk factor for NIDDM and that weight loss is not merely an unspecific preventive activity but constitutes a concrete form of treatment of NIDDM (see the first sentence and in particular the second sentence of the summary of document (11), which indicates that reduction of weight excess comes to the front line in the prevention and management of NIDDM [emphasis by the board]). This is confirmed in the original application on page 1, lines 7-8, which read: "The initial approach in treating obese patients affected with type II diabetes mellitus is weight reduction" [emphasis by the board]. As a consequence, treatment of NIDDM which is independent of weight loss, and treatment of NIDDM by weight loss, represent two subcategories of the treatment of NIDDM in general.

The respondent argued that page 1 of the original application contained a specific disclosure of the use of tetrahydrolipstatin for the treatment of type II diabetes mellitus per se. In particular, reference was made to the fact that the passage in lines 18-21, which concerns a prior-art citation (US-A-4 598 089), according to which tetrahydrolipstatin is a known compound useful for the control or prevention of obesity and hyperlipidemia, was immediately followed by the statement "[i]t has now surprisingly been found that a gastrointestinal lipase inhibitor, preferably tetrahydrolipstatin, when administered orally, is useful in the treatment and prevention of type II diabetes mellitus", which, according to the respondent, could in this context only mean treatment and prevention of type II diabetes mellitus per se, i.e. independent of weight loss.

The board cannot follow this reasoning: the passage on page 1, lines 18-27 says that in the prior art, tetrahydrolipstatin was used for the treatment of obesity and hyperlipidemia. In contrast, the present invention concerns the use of tetrahydrolipstatin for the treatment of type II diabetes mellitus, i.e. type II diabetes mellitus in general. There is, however, no reference in this passage as to whether said treatment is associated with or independent of weight loss. In other words, the subcategory "treatment of type II diabetes mellitus independent of weight loss" is not specifically disclosed therein.

This conclusion is not changed by the fact that the use of tetrahydrolipstatin for treating type II diabetes mellitus treatment is characterised as "surprising" (see page 1, line 23). It might be argued that including this judgmental term constitutes a pointer towards treatment of type II diabetes mellitus independent of weight loss, as treatment in combination with weight reduction would not be surprising in view of the statements further up on page 1 that (a) the initial approach in treating obese patients affected with type II diabetes mellitus is weight reduction (page 1, lines 7-8) and (b) tetrahydrolipstatin is known to be useful for the control or prevention of obesity and hyperlipidemia (page 1, lines 18-21). However, the disclosure of an amendment in the original application, no matter whether it is explicit or implicit, must be unambiguous and can therefore not be based on an evaluation of what the author of the original application might or might not consider as surprising. Moreover, the skilled person will read the original application in its entirety and learn from example 4 that weight reduction is an important issue in the present invention. Example 4, which concerns a study of patients suffering from NIDDM, emphasises that 30% of patients treated with tetrahydrolipstatin achieved at least a 5% reduction in baseline body weight.

The board therefore comes to the conclusion that the original application does not specifically disclose, neither by explicit nor by implicit disclosure, the use of tetrahydrolipstatin for the manufacture of an oral pharmaceutical preparation for treating type II diabetes mellitus per se, i.e. independent of weight reduction. The requirements of Article 123(2) EPC are therefore not met.

4. Auxiliary request I - Article 123(3) EPC

Deletion of "per se" from claim 1 of auxiliary request I means that, in contrast to the claims as granted, treatment by tetrahydrolipstatin is no longer restricted to type II diabetes mellitus independent of weight reduction, but encompasses treatment of any type of type II diabetes mellitus. In other words, the scope of protection has been extended from the treatment of a specific subcategory of NIDDM to NIDDM in general. As a consequence, the requirements of Article 123(3) EPC are not met.

5. Auxiliary request II - Article 123(2) EPC

Compared to the main request, the subject-matter of claim 1 of auxiliary request II has been narrowed down to the use of tetrahydrolipstatin for the manufacture of an oral hypoglycemic pharmaceutical preparation for treating type II diabetes mellitus. Such a use is not mentioned in the original application. The passage on page 1, lines 7-9, indicates that the initial treatment of obese patients affected with NIDDM is weight reduction and that other types of treatment include oral hypoglycemics and insulin. However, the combination of this passage, which concerns the prior art, with the statement in lines 23-25 of the same page that it has now surprisingly been found that tetrahydrolipstatin, when administered orally, is useful in the treatment and prevention of type II diabetes mellitus, does not provide a basis for its use for the manufacture of an oral hypoglycemic pharmaceutical preparation as claimed in claim 1 of auxiliary request II. As was already mentioned above (see third paragraph of point 3.2), the original application discloses the use of tetrahydro-lipstatin for the treatment of NIDDM in general. There is, however, no basis for the specific subcategory (dependent or independent, hypoglycemic, etc.). As a consequence, the requirements of Article 123(2) EPC are not met.

6. Auxiliary request III - Article 123(2) EPC

6.1 Compared to the main request, the subject-matter of claim 1 of auxiliary request III additionally comprises a disclaimer disclaiming obese subjects, thus restricting the treatment of NIDDM to non-obese subjects. According to decision G 2/10 of 30 August 2011, an amendment to a claim by the introduction of a disclaimer disclaiming from it subject-matter disclosed in the application as filed infringes Article 123(2) EPC if the subject-matter remaining in the claim after the introduction of the disclaimer is not, be it explicitly or implicitly, directly and unambiguously disclosed to the skilled person, using common general knowledge, in the application as filed (see point 1a of the order).

The original application discloses on page 1, lines 7-9 that the initial approach in treating obese patients affected with type II diabetes mellitus is weight reduction. Later on (see page 1, lines 18-21), tetrahydrolipstatin is mentioned as a known compound useful for the control or prevention of obesity and hyperlipidemia. However, as pointed out in point 5 above in connection with claim 1 of auxiliary request II, the combination of these passages concerning the prior art with the statement in lines 23-25 of the same page that it has now surprisingly been found that tetrahydrolipstatin, when administered orally, is useful in the treatment and prevention of type II diabetes mellitus, does not provide a basis for its use for the manufacture of an oral hypoglycemic pharmaceutical preparation for specific administration to non-obese patients. As mentioned above (see third paragraph of point 3.2), the original application discloses the use of tetrahydrolipstatin for the treatment of NIDDM in general. There is, however, no direct and unambiguous basis, be it by explicit or implicit disclosure, for specific subcategories such as the treatment of NIDDM in non-obese subjects. As a consequence, the requirements of Article 123(2) EPC are not met.

7. Reimbursement of the appeal fee

According to Article 113(1) EPC, the decisions of the European Patent Office may only be based on grounds or evidence on which the parties concerned have had an opportunity to present their comments. Established jurisprudence has interpreted this provision to mean that the comments presented must be considered in the ensuing decision. Thus, a decision which fails to take explicitly into account potentially refutative arguments submitted by a party contravenes Article 113(1) EPC, thereby constituting a substantial procedural violation (see decision T 0246/08 of 14 August 2008, point 2.2 of the reasons for the decision). In the present case, the contested patent was opposed inter alia under Article 100(b) EPC for insufficiency of disclosure. This ground of opposition was discussed at the oral proceedings. However, the decision under appeal, in which the patent and the invention to which it relates were found to meet the requirements of the EPC, does not contain any reasoning at all in connection with insufficiency of disclosure. Therefore, a substantial procedural violation has occurred.

The minutes of the oral proceedings reveal (see first paragraph on page 2) that the chairman of the opposition division announced after deliberation that the requirements of Article 83 EPC were met and that Article 100(b) EPC did not prejudice the maintenance of the patent, which means that the failure to consider sufficiency of disclosure had no influence on the final decision to maintain the patent in amended form. As a consequence, the board concludes that reimbursement of the appeal fee is not equitable, as the substantial procedural violation was not sufficiently closely linked to the need to pay the appeal fee.

Order

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.

3. The request for reimbursement of the appeal fee is refused.

Footer - Service & support
  • Service & support
    • FAQ
    • Contact us
    • Subscription centre
    • Official holidays
    • Publications
    • Procedural communications
    • Ordering
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility